Editorial
ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics
Abstract
On March 8, the final results of the ASSURE trial of adjuvant therapy for high-risk resected kidney cancer were published online on Lancet (1).
